TY - JOUR
T1 - Prostate Cancer, Use of Androgen Deprivation Therapy, and Cognitive Impairment
T2 - A Population-based Study
AU - Alonso Quiñones, Hector J.
AU - Stish, Bradley J.
AU - Hagen, Clinton
AU - Petersen, Ronald C.
AU - Mielke, Michelle M.
N1 - Publisher Copyright:
© 2020 Lippincott Williams and Wilkins. All rights reserved.
PY - 2020/4/1
Y1 - 2020/4/1
N2 - Introduction:The association of prostate cancer and androgen deprivation therapy (ADT) use with the odds of developing mild cognitive impairment (MCI) was determined in men from the population-based Mayo Clinic Study of Aging (MCSA).Methods:The study included 2513 men (mean age of 73.1 y) enrolled in the MCSA. A history of prostate cancer, ADT use, and length of ADT exposure before their first MCSA visit was abstracted using the Rochester Epidemiology Project medical records-linkage system. MCI was diagnosed at the baseline visit. Logistic regression was used to determine whether prostate cancer and ADT use was associated with odds of MCI.Results:Of the 2513 participants, 349 (13.9%) had a history of prostate cancer; among whom 99 (28.3%) were treated with ADT before MCSA enrollment. There were 382 (15.2%) with a diagnosis of MCI. In the univariate logistic regression models, prostate cancer (odds ratio, 1.50; 95% confidence interval, 1.12-2.00), and ADT exposure (odds ratio, 1.57; 95% confidence interval, 0.96-2.58) were associated with higher odds of MCI. These associations were greatly attenuated and not significant in multivariable models.Conclusions:Neither a diagnosis of prostate cancer nor ADT use was associated with odds of MCI in this cross-sectional population-based study.
AB - Introduction:The association of prostate cancer and androgen deprivation therapy (ADT) use with the odds of developing mild cognitive impairment (MCI) was determined in men from the population-based Mayo Clinic Study of Aging (MCSA).Methods:The study included 2513 men (mean age of 73.1 y) enrolled in the MCSA. A history of prostate cancer, ADT use, and length of ADT exposure before their first MCSA visit was abstracted using the Rochester Epidemiology Project medical records-linkage system. MCI was diagnosed at the baseline visit. Logistic regression was used to determine whether prostate cancer and ADT use was associated with odds of MCI.Results:Of the 2513 participants, 349 (13.9%) had a history of prostate cancer; among whom 99 (28.3%) were treated with ADT before MCSA enrollment. There were 382 (15.2%) with a diagnosis of MCI. In the univariate logistic regression models, prostate cancer (odds ratio, 1.50; 95% confidence interval, 1.12-2.00), and ADT exposure (odds ratio, 1.57; 95% confidence interval, 0.96-2.58) were associated with higher odds of MCI. These associations were greatly attenuated and not significant in multivariable models.Conclusions:Neither a diagnosis of prostate cancer nor ADT use was associated with odds of MCI in this cross-sectional population-based study.
KW - androgen deprivation therapy
KW - case-control study
KW - dementia
KW - prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=85077016213&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85077016213&partnerID=8YFLogxK
U2 - 10.1097/WAD.0000000000000366
DO - 10.1097/WAD.0000000000000366
M3 - Article
C2 - 31821185
AN - SCOPUS:85077016213
SN - 0893-0341
VL - 34
SP - 118
EP - 121
JO - Alzheimer disease and associated disorders
JF - Alzheimer disease and associated disorders
IS - 2
ER -